See-Mode Augmented Reporting Tool, Thyroid (SMART-T)
See-Mode Technologies Pte. Ltd. • Radiology • 09/09/2024
Device Purpose
The See-Mode Augmented Reporting Tool, Thyroid (SMART-T) is a machine learning-based software intended to enhance the analysis of thyroid ultrasound images by automatically localizing nodules and characterizing them using ACR TI-RADS descriptors. Clinical performance data indicates that SMART-T improves radiologists' accuracy in nodule localization, lexicon descriptor identification, and TI-RADS level agreement, thereby aiming to support more consistent and accurate thyroid ultrasound reporting.
Summary
See-Mode Augmented Reporting Tool, Thyroid (SMART-T) is a stand-alone, web-based software designed to assist medical professionals in analyzing thyroid ultrasound images for adult patients. It employs machine learning algorithms to process DICOM-compliant ultrasound images, automatically identifying and localizing suspicious soft tissue nodules. The software then characterizes these nodules by generating lexicon-based descriptors based on the American College of Radiology Thyroid Imaging, Reporting and Data System (ACR TI-RADS)—including composition, echogenicity, shape, margin, and echogenic foci—along with a calculated TI-RADS level. SMART-T facilitates structured reporting by generating an initial report from its analysis, which clinicians subsequently review, modify, and approve, and can also be used for reading measurements and annotations in further ultrasound studies. The device's efficacy was evaluated through standalone tests and a multi-reader multi-case (MRMC) study involving 18 radiologists and 600 patient cases. The MRMC study demonstrated that radiologists using SMART-T achieved improved performance: nodule localization accuracy increased (e.g., 95.6% aided vs. 93.6% unaided), and characterization of all ACR TI-RADS lexicon descriptors was significantly enhanced (e.g., margin accuracy rose from 57.3% unaided to 73.5% aided). Agreement with ground truth TI-RADS levels also improved (e.g., 60.0% aided vs. 51.1% unaided overall), particularly for clinically significant higher TR levels. The standalone performance of the software itself was robust, showing high accuracy in tasks like localization (95.1%) and TI-RADS level agreement (63.8%), with consistent results across diverse patient and reader subgroups.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the machine learning model's performance on specific TI-RADS descriptors, particularly 'Margin' (aided 73.5%, standalone 58.4%) and 'Echogenicity' (aided 77.4%, standalone 68.2%), where standalone performance is notably different from aided, impact the overall reliability and clinical utility of the generated TI-RADS level before radiologist review?; What were the specific criteria and processes used by the two expert US-board certified radiologists and the adjudicator to establish the 'ground truth' for localization and TI-RADS characterization, and how was inter-observer variability among these experts managed and quantified in the study?; The LROC analysis showed an AULROC improvement with the device (aided 0.758 vs. unaided 0.736 for IOU>0.5); how does this quantitative improvement translate to tangible clinical benefits, such as a reduction in the rate of unnecessary Fine Needle Aspirations (FNAs) or an increase in the detection of clinically significant malignancies?; Given that the dataset was 74% from the US and 81.5% female, what is the anticipated performance generalizability and potential variability when the SMART-T software is deployed in global populations with significantly different demographic characteristics, endemic goiter rates, or thyroid nodule prevalence?; While the study demonstrated improved TI-RADS level agreement and descriptor accuracy, what is the software's quantifiable impact on the radiologists' reporting workflow, specifically regarding the time taken to complete a thyroid ultrasound report and the consistency of reporting across radiologists with varying levels of experience?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Post-§524B but no clear network capability detected
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.
• Cybersecurity risk assessment not referenced in AI-generated device summary. FDA cybersecurity guidance (2023) expects this for cyber devices.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly